Early BCMA or standard triplet in RRMM—what’s your move?

High TLS risk starts, your prophylaxis choice could determine whether the patient lands in the ICU.

Intermediate-risk PE: anticoagulation… or add catheter-directed lysis?

Persistent chemo-induced thrombocytopenia: do you hold chemo again—or add a TPO-RA?

Acute VTE clinic visit: same indication, two DOACs—who bleeds less in the first 3 months?

High-risk AML + transplant + oral maintenance — are you using this in your practice?

Does every patient with mantle cell lymphoma still need upfront ASCT?

Relapsed DLBCL after multiple lines of therapy… what options remain?

Chronic Myeloid Leukemia: 2025 Update on Diagnosis, TKI Selection & Monitoring

Does Momelotinib Change Survival in Myelofibrosis? | SIMPLIFY Trials Explained

Asciminib vs Bosutinib in late-line CML: updated ASCEMBL results

Belumosudil for Chronic GVHD After Multiple Prior Lines | ROCKstar Trial Review

LUNA 3 in Blood: Does Rilzabrutinib Improve Durable Response in Chronic ITP?

Can CAR-T induce durable long-term control in relapsed/refractory follicular lymphoma?

5MinuteHematology Presentation